Latest PepGen News & Updates

See the latest news and media coverage for PepGen. We track all announcements, press releases, and industry mentions in real time, all in one place.

PepGen

Biotechnology company developing genetic therapies for neuromuscular and neurological diseases

pepgen.com

Headquarters: Boston, United States
Founded year: 2018
Company type: Public company
Number of employees: 65–200
Industry: Pharmaceuticals

Last updated November 10

Latest news about PepGen

In short: PepGen reported positive Phase 2 DM1 results and proposed a $125 million stock offering

Company announcements

November 10 PepGen

PepGen announces proposed $125.0 million public offering of common stock

Proceeds fund ongoing clinical development of its product candidate and working capital, with underwriters granted a 30-day option for $18.75 million more.

November 10 PepGen

PepGen reports positive Phase 2 FREEDOM2-DM1 10 mg/kg results

Mean splicing correction reaches 46.5%, with improvements in myotonia, grip strength, ambulation and mobility; PGN-EDODM1 is generally well tolerated with no serious adverse events.

August 6 PepGen

PepGen reports second quarter 2026 financial results

Net loss was $17.8 million and cash totaled $117.2 million; a DSMB recommended advancing PGN-EDODM1 into the 12.5 mg/kg cohort.

May 12 PepGen

PepGen reports first quarter 2026 financial results

Net loss was $17.8 million with $132.3 million cash; the 5 mg/kg FREEDOM2 cohort showed favorable safety and splicing, and the 10 mg/kg cohort is fully enrolled.

Media coverage

October 31 BioSpace

PepGen's DM1 oligonucleotide achieves best-in-class splicing

Mean splicing correction reached 46.5% at week 13, beating competitors' sub-30% results, as PepGen prepares to test a higher 12.5 mg/kg dose.

April 3 The National Law Review

PepGen Announces Regulatory Updates on FREEDOM2

- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in...

March 31 PharmaShots

PepGen Reports P-II (FREEDOM2-DM1) Trial Data of PGN-EDODM1 for Myotonic Dystrophy Type 1 - PharmaShots

Shots: PepGen has reported positive topline results from the 10mg/kg cohort of the P-II (FREEDOM2-DM1) MAD study evaluating PGN-EDODM1 (4 monthly IV doses; n=6) vs...

March 4 Morningstar

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

- DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to...

Never miss news about PepGen

Track PepGen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

PepGen competitors & trending companies

Browse news for competitors to PepGen and other trending companies.